Allarity Therapeutics Inc (ALLR)

$1.16 +0.03 (2.65%)
Market Cap 18.35M
Revenue (ttm) 320,000.00
Net Income (ttm) -24.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.12
Volume 55,100
Avg Vol 180,472
Day's Range N/A - N/A
Shares Out 15.82M
Stochastic %K 83%
Beta 0.01
Analysts Sell
Price Target $9.50

Company Profile

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2...

Industry: Biotechnology
Sector: Healthcare
Phone: 401 426 4664
Address:
24 School Street, 2nd Floor, Boston, United States
BetterDayzz
BetterDayzz Apr. 6 at 1:29 AM
$ALLR $10 minimum. Let the summer play out. Could go higher by end of year
0 · Reply
TupacLive
TupacLive Apr. 2 at 1:44 PM
$ALLR
0 · Reply
gms888777777
gms888777777 Apr. 1 at 5:09 PM
$ALLR Takeoffff news coming
0 · Reply
CantAffordMe
CantAffordMe Apr. 1 at 4:28 PM
$ALLR how did this toilet scam get $300K in sales?
1 · Reply
ganta7
ganta7 Mar. 31 at 1:22 PM
$ALLR company avg purchase price was $1.08 Will they add more ??? Webull don’t allow buy so can’t move but if company buys which they can will it move???
0 · Reply
ganta7
ganta7 Mar. 31 at 11:43 AM
$ALLR well they reported earnings yesterday but didn’t see any updates
0 · Reply
Ugly1
Ugly1 Mar. 30 at 8:07 PM
$ALLR under $1 tomorrow
1 · Reply
jrothman22
jrothman22 Mar. 29 at 12:58 AM
$ALLR Does anyone know how many patients we have in the Ph2 trial?
0 · Reply
CantAffordMe
CantAffordMe Mar. 27 at 2:43 PM
$ALLR lol fucking dogshit scam. how much money has jackass jensen paid himself since this scam started?
0 · Reply
Ugly1
Ugly1 Mar. 27 at 10:50 AM
$ALLR it’s coming…
0 · Reply
Latest News on ALLR
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Mar 31, 2026, 8:00 AM EDT - 5 days ago

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Mar 6, 2026, 8:00 AM EST - 4 weeks ago

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Feb 18, 2026, 8:15 AM EST - 6 weeks ago

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

Feb 3, 2026, 8:00 AM EST - 2 months ago

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

Dec 31, 2025, 8:00 AM EST - 3 months ago

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

Nov 14, 2025, 9:00 AM EST - 5 months ago

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Sep 22, 2025, 8:00 AM EDT - 6 months ago

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

Sep 17, 2025, 8:00 AM EDT - 7 months ago

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Aug 26, 2025, 8:00 AM EDT - 7 months ago

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

Aug 15, 2025, 4:30 PM EDT - 8 months ago

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

Jul 15, 2025, 8:00 AM EDT - 9 months ago

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

Jul 7, 2025, 8:00 AM EDT - 9 months ago

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Jun 27, 2025, 8:00 AM EDT - 10 months ago

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics Announces Changes to Board of Directors

Jun 11, 2025, 4:05 PM EDT - 10 months ago

Allarity Therapeutics Announces Changes to Board of Directors

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

May 9, 2025, 4:05 PM EDT - 11 months ago

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Apr 14, 2025, 9:04 AM EDT - 1 year ago

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Mar 14, 2025, 4:30 AM EDT - 1 year ago

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Mar 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Feb 24, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 14, 2025, 10:00 AM EST - 1 year ago

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Shareholders to Inquire about Securities Investigation

Feb 13, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Connect

Feb 12, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Reach Out

Feb 11, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation

Feb 10, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Investors to Learn More About the Investigation

Feb 9, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Investors to Learn More About the Investigation

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 7, 2025, 10:00 AM EST - 1 year ago

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect

Feb 6, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Feb 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation

Feb 4, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Reach Out

Feb 3, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out

Feb 2, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect

Jan 31, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Jan 30, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 8, 2025, 10:00 AM EST - 1 year ago

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Stockholders to Learn More About the Investigation

Jan 5, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Stockholders to Learn More About the Investigation

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Nov 18, 2024, 8:00 AM EST - 1 year ago

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Nov 11, 2024, 3:45 PM EST - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

DEADLINE TOMORROW: Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Reach Out To The Schall Law Firm

Nov 11, 2024, 11:15 AM EST - 1 year ago

DEADLINE TOMORROW: Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Reach Out To The Schall Law Firm

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm

Nov 9, 2024, 12:30 PM EST - 1 year ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm

ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Nov 8, 2024, 7:00 PM EST - 1 year ago

ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Nov 8, 2024, 9:45 AM EST - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Should Contact The Schall Law Firm

Nov 7, 2024, 11:00 AM EST - 1 year ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Should Contact The Schall Law Firm

The Schall Law Firm Encourages Stockholder Participation In A Case Against Allarity Therapeutics, Inc. For Fraud

Nov 6, 2024, 11:00 AM EST - 1 year ago

The Schall Law Firm Encourages Stockholder Participation In A Case Against Allarity Therapeutics, Inc. For Fraud

BetterDayzz
BetterDayzz Apr. 6 at 1:29 AM
$ALLR $10 minimum. Let the summer play out. Could go higher by end of year
0 · Reply
TupacLive
TupacLive Apr. 2 at 1:44 PM
$ALLR
0 · Reply
gms888777777
gms888777777 Apr. 1 at 5:09 PM
$ALLR Takeoffff news coming
0 · Reply
CantAffordMe
CantAffordMe Apr. 1 at 4:28 PM
$ALLR how did this toilet scam get $300K in sales?
1 · Reply
ganta7
ganta7 Mar. 31 at 1:22 PM
$ALLR company avg purchase price was $1.08 Will they add more ??? Webull don’t allow buy so can’t move but if company buys which they can will it move???
0 · Reply
ganta7
ganta7 Mar. 31 at 11:43 AM
$ALLR well they reported earnings yesterday but didn’t see any updates
0 · Reply
Ugly1
Ugly1 Mar. 30 at 8:07 PM
$ALLR under $1 tomorrow
1 · Reply
jrothman22
jrothman22 Mar. 29 at 12:58 AM
$ALLR Does anyone know how many patients we have in the Ph2 trial?
0 · Reply
CantAffordMe
CantAffordMe Mar. 27 at 2:43 PM
$ALLR lol fucking dogshit scam. how much money has jackass jensen paid himself since this scam started?
0 · Reply
Ugly1
Ugly1 Mar. 27 at 10:50 AM
$ALLR it’s coming…
0 · Reply
sixmilliondollarman
sixmilliondollarman Mar. 25 at 9:23 PM
$ALLR CEO of Life Biosciences is also chairman Allarity board 🤷‍♂️
1 · Reply
SaulGoodmanz
SaulGoodmanz Mar. 24 at 6:14 PM
$ALLR anyone know why you can’t buy on Webull?
2 · Reply
BadBankofGotham
BadBankofGotham Mar. 23 at 4:34 PM
Holding $BRTX $FEED $ADTX and $ALLR
1 · Reply
Kvakklunch
Kvakklunch Mar. 23 at 8:58 AM
$ALLR Ref Fintel Shares short available are rising, while stock price is dumping. Weird.
2 · Reply
MidNightglow
MidNightglow Mar. 22 at 10:42 PM
$IMTE Recent filings (February and March 2026) highlight a "going concern" risk. $ALLR $20 Million Debt Financing (March 6, 2026): Allarity closed a non-convertible debt financing deal with Streeterville Capital
0 · Reply
Ugly1
Ugly1 Mar. 20 at 8:32 PM
$ALLR it’ll be back back down to $1 soon enough, just be patient 👊😁
0 · Reply
RAKIN13
RAKIN13 Mar. 20 at 4:39 PM
$ALLR :(
0 · Reply
Ugly1
Ugly1 Mar. 19 at 10:57 PM
$ALLR tried to tell y’all…might have to get back in and flip again now 😂
2 · Reply
sixmilliondollarman
sixmilliondollarman Mar. 19 at 6:50 PM
$ALLR 👀 opened small position
0 · Reply
biotrade123
biotrade123 Mar. 19 at 3:17 PM
$ALLR
0 · Reply
CantAffordMe
CantAffordMe Mar. 19 at 1:41 PM
$ALLR do you guys think this diarrhea will at least hold $1.00
1 · Reply
biotrade123
biotrade123 Mar. 18 at 6:30 PM
$ALLR back to $1??
0 · Reply